Conquer Cold and Cough with Dextromethorphan Hydrobromide, Chlorpheniramine Maleate and Phenylephrine Hydrochloride!
1. Oh S, Agrawal S, Sabir S, Taylor A. Dextromethorphan.
2. Eccles, R., Fietze, I. and Rose, U.-B. (2014) Rationale for Treatment of Common Cold and Flu with Multi-Ingredient Combination Products for Multi-Symptom Relief in Adults. Open Journal of Respiratory Diseases, 4, 73-82. http://dx.doi.org/10.4236/ojrd.2014.43011.
3. Zedex plus PI 2024
Where to use?
- Dextromethorphan, Chlorpheniramine, and Phenylephrine are commonly used in combination to treat symptoms associated with the common cold and upper respiratory tract infections.
- They are typically used to relieve:
Cough: Dextromethorphan acts as a cough suppressant.
Nasal Congestion: Phenylephrine helps to reduce nasal congestion by constricting blood vessels.
Runny Nose and Sneezing:
Chlorpheniramine alleviates symptoms such as runny nose and sneezing by blocking histamine receptors.
1. Oh S, Agrawal S, Sabir S, Taylor A. Dextromethorphan.
2. Livier Castillo J, et al. The Use and Efficacy of Oral Phenylephrine Versus Placebo Treating Nasal Congestion Over the Years on Adults: A Systematic Review. Cureus. 2023 Nov 19;15(11):e49074.
3. Zedex plus PI 2024
How to use?
- Shake the syrup bottle well before use to ensure that the ingredients are evenly distributed
- Measure the dose with a measuring cap and ensure correct oral doses.
- Check the instructions on the label thoroughly before use.
- For Adults and children >12 years -10ml 2-3 times a day.
- ZEDEX PLUS can be taken with or without food, but taken as per physicians direction.
1. Zedex plus PI 2024
Possible Side effects
- Dizziness
- Dry mouth
- Headache
- Sleep disturbances
- Palpitations
- Rashes or itching
- Blurred Vision
- GI disturbance
(Nausea-vomiting, constipation, heartburn or anorexia)
1. Zedex plus PI 2024
Safety Advises
Alcohol:
Caution is advised when consuming alcohol with ZEDEX PLUSRx. Please consult your doctor.
Pregnancy and Lactation:
Please consult your doctor if you are pregnant, breastfeeding, or planning to conceive during the treatment. This medication may cause fetal harm or be secreted in breast milk. Your doctor will weigh the benefits and potential risks before prescribing it to you.
Caution:
Caution should be maintained in patients with history of cardiac disorders, diabetes or peripheral vascular disease.
Driving:
Please drive with caution while on the medication and drive only if necessary. ZEDEX PLUSRx may cause your vision to blur and may cause dizziness, which involves risk in driving.
1. Zedex plus PI 2024
Why this combination?
CHLORPHENIRAMINE; DEXTROMETHORPHAN; PHENYLEPHRINE is a combination of an antihistamine, a cough suppressant, and a decongestant. When combined, these medications provide a multi-symptom approach to treating cold and allergy symptoms.1
Here’s how they complement each other:2,3,4
Cough Suppression:
Dextromethorphan helps manage coughs, which can be particularly bothersome during colds.
Allergy Relief:
Chlorpheniramine addresses the histamine-related symptoms, reducing sneezing, itching, and runny nose.
Nasal Congestion Relief:
Phenylephrine helps clear nasal congestion, making it easier to breathe.
1. Chlorpheniramine; Dextromethorphan; Phenylephrine oral solution or syrup. Available at: https://my.clevelandclinic.org/health/drugs/ 19488-chlorpheniramine-dextromethorphan-phenylephrine-oral-solution-or-syrup. Accessed on 15th July 2024.
2. Oh S, Agrawal S, Sabir S, Taylor A. Dextromethorphan.
3. Livier Castillo J, et al. The Use and Efficacy of Oral Phenylephrine Versus Placebo Treating Nasal Congestion Over the Years on Adults: A Systematic Review. Cureus. 2023 Nov 19;15(11):e49074.
4. Zedex plus PI 2024.
Editor's Pick
Did You Hear? DXM 15 Can Transform Your Patients' Cough
Did You Hear? DXM 15 Can Transform Your Patients' Cough
Did You Hear? DXM 15 Can Transform Your Patients' CoughThe Cough Combo That Everyone Approves
The Cough Combo That Everyone Approves
The Cough Combo That Everyone ApprovesDextromethorphan Fixed Dose Combinations now recommended by Indian Chest Society
Dextromethorphan Fixed Dose Combinations now recommended by Indian Chest Society
ZEDEX PLUS with Dextromethorphan Fixed-Dose Combinations offers proven efficacy and superior patient outcomes. Even the Indian Chest Society endorses it!Dextromethorphan Fixed Dose Combinations now recommended by Indian Chest Society
Taste the Difference with Mouthfeel that Delivers!
Taste the Difference with Mouthfeel that Delivers!
Don’t settle let your patients settle for less—choose ZEDEX PLUS for a cough syrup that's smooth, effective, and loved by 240 patients!Taste the Difference with Mouthfeel that Delivers!
ZEDEX PLUS’s syrup ranks at the top in all organoleptic properties
ZEDEX PLUS’s syrup ranks at the top in all organoleptic properties
ZEDEX PLUS soars high in scoring top ranks amongst other players in the market. 240 patients also say so!ZEDEX PLUS’s syrup ranks at the top in all organoleptic properties
ZEDEX PLUS is winning over patients with its taste and colour
ZEDEX PLUS is winning over patients with its taste and colour
Wave goodbye to that annoying cough with ZEDEX PLUS! Not only does it work wonders, but it also tastes amazing.ZEDEX PLUS is winning over patients with its taste and colour
X-ray patterns and insights for different cough categories
X-ray patterns and insights for different cough categories
Analyzing X-rays across various categories of cough patients, such as smokers' cough, bronchospastic cough (Asthma), infectious cough (Pneumonia), and postnasal drip cough—offers valuable insights into each condition.X-ray patterns and insights for different cough categories
The impact of long-lasting coughs on diverse patient population
The impact of long-lasting coughs on diverse patient population
Chronic coughs worsen health for those with diabetes, GERD, asthma, COPD, heart issues, allergies, & the elderly. They disrupt blood sugar, increase reflux, trigger asthma attacks, obstruct breathing, stress the heart, & heighten allergy sensitivity.The impact of long-lasting coughs on diverse patient population
Impact of untreated long-lasting cough in patients
Impact of untreated long-lasting cough in patients
Chronic cough affects more women than men and can lead to fatigue, sleep disturbances, musculoskeletal pain & psychological issues like anxiety. It may worsen asthma or GERD. Severe coughing episodes can cause rib fractures and urinary incontinence.Impact of untreated long-lasting cough in patients
Decode the 8 week long lasting cough!
Decode the 8 week long lasting cough!
Identifying patients with chronic cough involves assessing symptoms, past infections, smoking history, medication use, and environmental exposure. Common red flags include coughing up blood, shortness of breath, and conditions like asthma or GERD.Decode the 8 week long lasting cough!
Cough Sound Analysis in Adults for Better Diagnosis
Cough Sound Analysis in Adults for Better Diagnosis
Cough sounds can be distinct based on the underlying cause of cough. Clinicians can get a lead to diagnosis, based on the analysis of cough sounds. Some of the common cough sounds are listed below:
1. A brassy cough occurs when an intrathoracic tumor (such as an aneurysm or mediastinal tumor) compresses the trachea, resulting in a cough with a metallic or harsh tonal quality, typically involving the trachea or bronchi.
2. A bovine cough manifests when a tumor affects the recurrent laryngeal nerve, altering the normal vocal cord movement. This results in a prolonged, less forceful cough often accompanied by wheezing.
3. A whooping cough is identified by a characteristic "whoop" sound as air is forcefully inhaled between coughing fits, common in pertussis.
4. A hysterical cough is typically loud and repetitive, often with a bark-like quality, and can be psychogenic in origin.
5. A barking cough (commonly associated with croup) involves noisy, high-pitched breathing sounds during both inhalation and exhalation due to subglottic pathology.
6. A paroxysmal cough is marked by intense, violent coughing episodes, often seen in conditions like bronchial asthma or heart failure.
7. A persistent cough with productive sputum, especially worse in the mornings and lasting for months or years, is characteristic of chronic bronchitis.
This classification aids in the clinical assessment of coughs, helping identify underlying pathologies based on auditory characteristics.
Cough Sound Analysis in Adults for Better Diagnosis
Cough Sound Analysis in Adults for Better Diagnosis
Cough sounds can be distinct based on the underlying cause of cough. Clinicians can get a lead to diagnosis, based on the analysis of cough sounds. Some of the common cough sounds are listed below:
1. A brassy cough occurs when an intrathoracic tumor (such as an aneurysm or mediastinal tumor) compresses the trachea, resulting in a cough with a metallic or harsh tonal quality, typically involving the trachea or bronchi.
2. A bovine cough manifests when a tumor affects the recurrent laryngeal nerve, altering the normal vocal cord movement. This results in a prolonged, less forceful cough often accompanied by wheezing.
3. A whooping cough is identified by a characteristic "whoop" sound as air is forcefully inhaled between coughing fits, common in pertussis.
4. A hysterical cough is typically loud and repetitive, often with a bark-like quality, and can be psychogenic in origin.
5. A barking cough (commonly associated with croup) involves noisy, high-pitched breathing sounds during both inhalation and exhalation due to subglottic pathology.
6. A paroxysmal cough is marked by intense, violent coughing episodes, often seen in conditions like bronchial asthma or heart failure.
7. A persistent cough with productive sputum, especially worse in the mornings and lasting for months or years, is characteristic of chronic bronchitis.
This classification aids in the clinical assessment of coughs, helping identify underlying pathologies based on auditory characteristics.
Application of the CHIldren with acute COugh (CHICO) framework to enhance the management of antibiotics
Application of the CHIldren with acute COugh (CHICO) framework to enhance the management of antibiotics
Recent research demonstrated that the CHIldren with acute COugh (CHICO) intervention is a valuable tool for clinicians to make decisions about antibiotic prescriptions and engage with caregivers about their worries and treatment options. Adjusting the intervention might be necessary to create a better fit with how clinicians manage their consultations, both in traditional settings and through remote means. The data from this study were presented in The British Journal of General Practice.
Interviews were conducted to assess the acceptability and utilization of the CHICO intervention. Various healthcare providers from clinics with different antibiotic dispensing patterns, including those with high and low rates, were recruited for the study. The data collection and thematic analysis were based on normalization process theory.
Clinicians generally found the intervention to be beneficial because it was straightforward and quick to implement, allowing them to address carer concerns while reassuring both themselves and the carers about the treatment decisions being made. However, it was mainly used as a supportive tool for treatment choices rather than a method for changing behavior. The advice leaflet that came with it was useful for explaining treatment decisions and encouraging self-care. There were instances where the intervention did not align with the clinicians' standard procedures, which could hinder its application. As familiarity with the algorithm grew, the reliance on interventions decreased, a trend that increased during the COVID-19 pandemic when practices changed and remote consultations became more common.
In summary, the CHICO intervention serves as a valuable resource for healthcare professionals. It helps clinicians make informed decisions about antibiotic prescriptions and encourages discussions with caregivers regarding their concerns and available treatment options.
Application of the CHIldren with acute COugh (CHICO) framework to enhance the management of antibiotics
Application of the CHIldren with acute COugh (CHICO) framework to enhance the management of antibiotics
Recent research demonstrated that the CHIldren with acute COugh (CHICO) intervention is a valuable tool for clinicians to make decisions about antibiotic prescriptions and engage with caregivers about their worries and treatment options. Adjusting the intervention might be necessary to create a better fit with how clinicians manage their consultations, both in traditional settings and through remote means. The data from this study were presented in The British Journal of General Practice.
Interviews were conducted to assess the acceptability and utilization of the CHICO intervention. Various healthcare providers from clinics with different antibiotic dispensing patterns, including those with high and low rates, were recruited for the study. The data collection and thematic analysis were based on normalization process theory.
Clinicians generally found the intervention to be beneficial because it was straightforward and quick to implement, allowing them to address carer concerns while reassuring both themselves and the carers about the treatment decisions being made. However, it was mainly used as a supportive tool for treatment choices rather than a method for changing behavior. The advice leaflet that came with it was useful for explaining treatment decisions and encouraging self-care. There were instances where the intervention did not align with the clinicians' standard procedures, which could hinder its application. As familiarity with the algorithm grew, the reliance on interventions decreased, a trend that increased during the COVID-19 pandemic when practices changed and remote consultations became more common.
In summary, the CHICO intervention serves as a valuable resource for healthcare professionals. It helps clinicians make informed decisions about antibiotic prescriptions and encourages discussions with caregivers regarding their concerns and available treatment options.
Montelukast Sodium Combination Therapy Significantly Improves Outcomes in Pediatric Cough Variant Asthma
Montelukast Sodium Combination Therapy Significantly Improves Outcomes in Pediatric Cough Variant Asthma
A recent meta-analysis has demonstrated the clinical efficacy of montelukast sodium combination therapy for children with cough variant asthma (CVA). This study reviewed 18 clinical trials from Chinese populations, comparing combination therapy (montelukast sodium plus standard treatments) to control treatments, which included budesonide, fluticasone propionate, salmeterol-fluticasone, or ketotifen alone.
The analysis revealed that the combination therapy group had a significantly higher effective treatment rate (relative ratio [RR]: 1.23, 95% confidence interval [CI]: 1.18-1.29, p < 0.001) than the control group, with no significant difference in adverse reactions between groups (RR: 0.65, 95% CI: 0.42-1.02, p = 0.060).
Pulmonary function parameters, including peak expiratory flow (PEF), forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and FEV1/FVC ratios, were significantly improved in the combination therapy group compared to controls (p < 0.001).
Moreover, the combined therapy resulted in significantly lower levels of inflammatory markers, including tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), and IgE, indicating better control of airway inflammation (p < 0.001).
This meta-analysis highlights that montelukast sodium, when used alongside standard asthma treatments, provides superior clinical outcomes in managing pediatric CVA. These findings support the use of combination therapy as a practical approach to improving both respiratory function and inflammation control in children with CVA.
Montelukast Sodium Combination Therapy Significantly Improves Outcomes in Pediatric Cough Variant Asthma
Montelukast Sodium Combination Therapy Significantly Improves Outcomes in Pediatric Cough Variant Asthma
A recent meta-analysis has demonstrated the clinical efficacy of montelukast sodium combination therapy for children with cough variant asthma (CVA). This study reviewed 18 clinical trials from Chinese populations, comparing combination therapy (montelukast sodium plus standard treatments) to control treatments, which included budesonide, fluticasone propionate, salmeterol-fluticasone, or ketotifen alone.
The analysis revealed that the combination therapy group had a significantly higher effective treatment rate (relative ratio [RR]: 1.23, 95% confidence interval [CI]: 1.18-1.29, p < 0.001) than the control group, with no significant difference in adverse reactions between groups (RR: 0.65, 95% CI: 0.42-1.02, p = 0.060).
Pulmonary function parameters, including peak expiratory flow (PEF), forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and FEV1/FVC ratios, were significantly improved in the combination therapy group compared to controls (p < 0.001).
Moreover, the combined therapy resulted in significantly lower levels of inflammatory markers, including tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), and IgE, indicating better control of airway inflammation (p < 0.001).
This meta-analysis highlights that montelukast sodium, when used alongside standard asthma treatments, provides superior clinical outcomes in managing pediatric CVA. These findings support the use of combination therapy as a practical approach to improving both respiratory function and inflammation control in children with CVA.
Insights from the Tasmanian Longitudinal Health Study Identifies Treatable Traits in Adult Cough Subclasses
Insights from the Tasmanian Longitudinal Health Study Identifies Treatable Traits in Adult Cough Subclasses
Cough is a prevalent yet complex condition with distinct subclasses, but its characteristics and progression over time remain poorly understood in general populations. This study analyzed data from the Tasmanian Longitudinal Health Study (TAHS), a prospective community-based cohort that began in 1968, following participants from childhood to midlife. We aimed to identify cough subclasses among adults and explore their clinical features and lung function trajectories over six decades.
Data were collected from 8,583 baseline participants, with 6,128 traced and invited for follow-up between 2012 and 2016. Of the 3,609 respondents, 2,213 were identified as current coughers and classified into six cough subclasses through latent class analysis: minimal cough (9.3%), cough with colds only (53.7%), cough with allergies (13.8%), intermittent productive cough (9.6%), chronic dry cough (6.6%), and chronic productive cough (6.9%). Chronic and intermittent productive coughers had significantly worse lung function trajectories, such as persistent low FEV1 and early low-rapid decline in FEV1/FVC, compared to those with minimal cough.
These findings reveal distinct treatable traits across cough subclasses, such as asthma, allergies, and smoking, particularly in productive cough types. They underscore the need for tailored management strategies in primary care, including routine spirometry for productive cough, distinct from those used for dry cough, suggesting that future studies could refine cough management in community settings.
Insights from the Tasmanian Longitudinal Health Study Identifies Treatable Traits in Adult Cough Subclasses
Insights from the Tasmanian Longitudinal Health Study Identifies Treatable Traits in Adult Cough Subclasses
Cough is a prevalent yet complex condition with distinct subclasses, but its characteristics and progression over time remain poorly understood in general populations. This study analyzed data from the Tasmanian Longitudinal Health Study (TAHS), a prospective community-based cohort that began in 1968, following participants from childhood to midlife. We aimed to identify cough subclasses among adults and explore their clinical features and lung function trajectories over six decades.
Data were collected from 8,583 baseline participants, with 6,128 traced and invited for follow-up between 2012 and 2016. Of the 3,609 respondents, 2,213 were identified as current coughers and classified into six cough subclasses through latent class analysis: minimal cough (9.3%), cough with colds only (53.7%), cough with allergies (13.8%), intermittent productive cough (9.6%), chronic dry cough (6.6%), and chronic productive cough (6.9%). Chronic and intermittent productive coughers had significantly worse lung function trajectories, such as persistent low FEV1 and early low-rapid decline in FEV1/FVC, compared to those with minimal cough.
These findings reveal distinct treatable traits across cough subclasses, such as asthma, allergies, and smoking, particularly in productive cough types. They underscore the need for tailored management strategies in primary care, including routine spirometry for productive cough, distinct from those used for dry cough, suggesting that future studies could refine cough management in community settings.
Insights from the RHINESSA Study suggest Chronic Cough to be Heritable Across Generations
Insights from the RHINESSA Study suggest Chronic Cough to be Heritable Across Generations
This study investigated the heritability of chronic cough, examining whether individuals with chronic cough are more likely to have offspring who also develop cough, and whether this association varies by cough type (productive vs. nonproductive).
The RHINESSA Generation Study included 7,155 parents aged 30-54 who completed detailed questionnaires in 2000 and 2010, and 8,176 offspring aged ≥20 who completed similar questionnaires between 2012-2019. Chronic cough was classified as either productive or nonproductive. Mixed-effects logistic regression analyses were conducted to assess the associations between parental and offspring cough, adjusting for multiple factors including offspring age, sex, body mass index, smoking history, asthma, rhinitis, gastroesophageal reflux, and parental smoking.
Results indicated that offspring of parents with nonproductive cough had a higher prevalence of nonproductive cough (11%) compared to those with parents without nonproductive cough (7%), with an adjusted odds ratio (aOR) of 1.59 (95% CI: 1.20-2.10). Similarly, offspring of parents with productive cough had a higher prevalence of productive cough (14%) compared to those with non-productive cough parents (11%), with an aOR of 1.34 (95% CI: 1.07-1.67). No significant associations were found between mismatched cough types.
These findings suggest that chronic cough, independent of asthma, may be a distinct heritable trait with type-specific transmission patterns.
Insights from the RHINESSA Study suggest Chronic Cough to be Heritable Across Generations
Insights from the RHINESSA Study suggest Chronic Cough to be Heritable Across Generations
This study investigated the heritability of chronic cough, examining whether individuals with chronic cough are more likely to have offspring who also develop cough, and whether this association varies by cough type (productive vs. nonproductive).
The RHINESSA Generation Study included 7,155 parents aged 30-54 who completed detailed questionnaires in 2000 and 2010, and 8,176 offspring aged ≥20 who completed similar questionnaires between 2012-2019. Chronic cough was classified as either productive or nonproductive. Mixed-effects logistic regression analyses were conducted to assess the associations between parental and offspring cough, adjusting for multiple factors including offspring age, sex, body mass index, smoking history, asthma, rhinitis, gastroesophageal reflux, and parental smoking.
Results indicated that offspring of parents with nonproductive cough had a higher prevalence of nonproductive cough (11%) compared to those with parents without nonproductive cough (7%), with an adjusted odds ratio (aOR) of 1.59 (95% CI: 1.20-2.10). Similarly, offspring of parents with productive cough had a higher prevalence of productive cough (14%) compared to those with non-productive cough parents (11%), with an aOR of 1.34 (95% CI: 1.07-1.67). No significant associations were found between mismatched cough types.
These findings suggest that chronic cough, independent of asthma, may be a distinct heritable trait with type-specific transmission patterns.
How would you rate this Medshorts
Thank you !
Your rating has been recorded.
Videos Speakers
Q1: What are the active ingredients in ZEDEX PLUS?
A: ZEDEX PLUS contains a blend of active ingredients, including a cough suppressant, a decongestant, and an antihistamine.
Q2: How does ZEDEX PLUS work?
A: ZEDEX PLUS works by suppressing the cough reflex, reducing nasal congestion, and relieving symptoms of allergy such as runny nose and sneezing.
Q3: Is ZEDEX PLUS available over the counter?
A: Yes, ZEDEX PLUS is available over the counter, but it is recommended to consult with a healthcare provider before use.
Q4: What symptoms does ZEDEX PLUS treat?
A: ZEDEX PLUS treats cough, nasal congestion, runny nose, and other symptoms associated with the common cold and allergies.
Q5: How should I take ZEDEX PLUS?
A: Take ZEDEX PLUS as directed on the package or by your healthcare provider, usually with or without food.
Q6: What is the recommended dosage for adults?
A: The recommended dosage for adults is specified on the packaging or by your healthcare provider. Do not exceed the recommended dose.
Q7: Can I take ZEDEX PLUS with food?
A: Yes, ZEDEX PLUS can be taken with or without food.
Q8: What should I do if I miss a dose?
A: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double up to make up for the missed dose.
Q9: How long can I take ZEDEX PLUS?
A: Do not take ZEDEX PLUS for more than 7 days without consulting your healthcare provider.
Q10: Who should not take ZEDEX PLUS?
A: Individuals allergic to any ingredients, or those with certain medical conditions such as high blood pressure or heart disease, should avoid ZEDEX PLUS. Consult your healthcare provider for more information.
Q11: Can I take ZEDEX PLUS with other medications?
A: Always consult your healthcare provider before combining ZEDEX PLUS with other medications to avoid potential interactions.
Q12: Can I drink alcohol while taking ZEDEX PLUS?
A: Avoid alcohol while taking ZEDEX PLUS, as it can increase the risk of drowsiness and dizziness.
Q13: Is ZEDEX PLUS safe for children?
A: ZEDEX PLUS should be used in children only under the supervision of a healthcare provider and according to the recommended dosage.
Q14: How should I store ZEDEX PLUS?
A: Store ZEDEX PLUS at room temperature, away from light and moisture. Keep it out of reach of children.
Q15: What should I do if I accidentally overdose?
A: In case of an overdose, seek medical attention immediately. Overdose symptoms may include severe drowsiness, confusion, and difficulty breathing.
Q16: Can I share ZEDEX PLUS with someone else?
A: Do not share ZEDEX PLUS with others, as it is prescribed based on individual health conditions and needs.
Q17: How long does it take for ZEDEX PLUS to work?
A: ZEDEX PLUS typically starts to relieve symptoms within 30 minutes to an hour.
GGI-CO-A1-AQS-300033343-WM-G24-1630
Below fields are needed for webinar purpose.